Forbon(300387)2023-10-26 16:00Financial Performance - The company's revenue for Q3 2023 reached ¥279,309,042.66, representing a 33.39% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥25,732,805.52, a significant increase of 65.75% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥24,451,841.47, up 69.56% from the previous year[4] - Total operating revenue for the period reached ¥750,445,015.21, an increase of 26.3% compared to ¥594,414,790.11 in the previous period[25] - The net profit for the third quarter of 2023 was CNY 58,185,882.43, an increase of 24.6% compared to CNY 46,709,181.74 in the same period last year[27] - The total comprehensive income for the third quarter was CNY 74,495,052.81, significantly higher than CNY 29,403,355.18 in the previous year[28] - Basic and diluted earnings per share increased to CNY 0.2124 from CNY 0.1579 year-over-year[28] Cash Flow and Assets - The operating cash flow net amount for the year-to-date period was ¥60,461,898.96, a remarkable increase of 2,003.66%[4] - The company's cash and cash equivalents stood at ¥272,715,360.60, slightly up from ¥271,362,136.37 at the start of the year[22] - Cash flow from operating activities generated a net inflow of CNY 60,461,898.96, compared to a net inflow of CNY 2,874,122.62 in the same period last year[28] - The company reported cash inflows from investment activities of CNY 177,756,928.29, up from CNY 152,237,188.51 in the previous year[29] - Cash outflows for investment activities totaled CNY 271,158,446.96, compared to CNY 188,471,582.53 in the same period last year[29] - The net cash flow from financing activities was CNY 30,952,383.28, a recovery from a net outflow of CNY 57,606,920.94 in the previous year[29] - The cash and cash equivalents at the end of the period increased to CNY 272,715,360.60 from CNY 219,427,159.07 year-over-year[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,680, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Yingcheng Fubon Technology Co., Ltd., holds 30.01% of the shares, equating to 86,738,380 shares[13] - The second-largest shareholder, Northland Chemicals Investment Limited, holds 5.61% of the shares, totaling 16,214,046 shares[13] - The top 10 shareholders hold a significant portion of the company's shares, with the largest three shareholders accounting for over 39% of total shares[13] - The company has no preferred shareholders as of the reporting period[15] Investments and Projects - The company has completed a capital contribution of $10 million for the joint venture established with OCP S.A., with both parties holding 50% of the shares[17] - The Fubon Gao Investment Fund has invested in 6 projects, with a total capital contribution of 100 million RMB[19] - The fund's investment project, Wuhan Heyuan Biotechnology Co., Ltd., completed its IPO application on December 29, 2022, and has progressed through feedback rounds[19] Operational Metrics - The company's basic earnings per share for Q3 2023 was ¥0.089, up 65.74% year-on-year[4] - The weighted average return on equity for the year-to-date period was 4.80%, an increase of 0.96% compared to the previous year[4] - The company reported a net profit margin improvement, with net profit increasing due to higher revenue and controlled costs[25] - Research and development expenses increased to ¥23,286,746.76, representing a rise of 20.5% from ¥19,382,679.68[25] Liabilities and Equity - Total assets as of September 30, 2023, amounted to ¥1,879,937,930.66, reflecting a 10.25% increase from the end of the previous year[4] - The total liabilities decreased to ¥533,715,965.73 from ¥443,290,382.97, indicating a reduction of 20.4%[24] - The equity attributable to shareholders increased to ¥1,312,025,828.62, up from ¥1,249,028,157.98, marking a growth of 5.0%[24] Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance competitive positioning[25] Legal Matters - The company is involved in an arbitration case regarding the payment for the remaining equity of Holland Novozymes, with a court hearing expected in November 2023[20] Miscellaneous - The company has not undergone an audit for the third quarter report[30]